Shockwave Medical, Inc. (NASDAQ:SWAV) Q4 2023 Earnings Conference Call February 15, 2024 4:30 PM ET

Company Participants

Debbie Kaster - VP, IR

Doug Godshall - President and CEO

Isaac Zacharias - President and CCO

Renee Gaeta - CFO

Robert Fletcher - SVP, Marketing & Market Access

Conference Call Participants

Adam Maeder - Piper Sandler

Bill Plovanic - Canaccord

Patrick Wood - Morgan Stanley

Travis Steed - Bank of America

Larry Biegelsen - Wells Fargo

Michael Polark - Wolfe Research

Mike Kratky - Leerink Partners

Mike Matson - Needham & Company

Imron Zafar - Deutsche Bank

Danielle Antalffy - UBS

Operator

Good afternoon and welcome to ShockWave's Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Debbie Kaster, Vice President of Investor Relations at ShockWave for a few introductory comments.

Debbie Kaster

Thank you all for participating in today's call. Joining me today from ShockWave Medical are Doug Godshall, President and Chief Executive Officer; Isaac Zacharias, President and Chief Commercial Officer; and Renee Gaeta, Chief Financial Officer. Earlier today, ShockWave released financial results for the quarter and year ended December 31st, 2023. A copy of the press release is available on ShockWave's website.

Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Any statements contained in this call other than statements of historical fact are forward-looking statements. All forward-looking statements, including, without limitation, statements relating to our sales and operating trends, business and hiring prospects, financial and revenue expectations, clinical trials, reimbursement proposals, and future product development and approvals are based upon our current estimates and various assumptions.

These statements involve material risks and uncertainties, including the impact of global business, political, and macroeconomic conditions that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements.

For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our annual report on Form 10-K on file with the SEC and available on EDGAR, and in our other reports filed periodically with the SEC.